One vision —
a cancer-free future.
Unlike surgery, chemotherapy and radiation, cell and gene therapies harness the power of your immune system to destroy cancer cells without harming healthy tissue. We fund the research that will make this vision a reality.
FDA approves first engineered T-cell therapy for solid tumor
The FDA approved a T-cell receptor (TCR) therapy to treat metastatic or unresectable synovial sarcoma.
Celebrating Laurie Adami's 6-year CAR T-cell anniversary
On July 16, 2018, Laurie Adami received her CAR T cells. She has been cancer-free ever since they defeated her lymphoma.
ACGT awards grant for development of remote-controlled CAR T cells
This is the second research grant awarded to scientist Crystal Mackall, MD (Stanford University).
Q&A with ACGT Chief Program Officer Barbara Lavery
Chief Program Officer Barbara Lavery talks about her career and work with ACGT.
Our direct impact on eradicating all cancer.
Collaborating with partners and funding research fellows, we are transforming cancer treatments today while bringing the world closer to a cure for all cancers tomorrow.
37+
million dollars invested in groundbreaking research.
67
research fellows awarded grants.
41
top medical institutions and partners funded.
Join forces with the world’s leading researchers to finally identify cures.
Cell and gene therapies harness the power of a patient’s own immune system to destroy cancer cells without harming healthy tissue.
E. Antonio Chiocca, MD, PhD
Brigham and Women’s Hospital
Using viruses to infect glioblastoma cancer cells and engage a patient’s immune system to join the fight.
Crystal Mackall, MD
Stanford University
Training CAR T cells to find and kill cancers that express the GD2 biomarker, including osteosarcoma, pediatric neuroblastoma and diffuse intrinsic pontine glioma.
Juan Fueyo, MD
MD Anderson Cancer Center
ACGT is funding research that uses an oncolytic virus to fight glioblastoma, a deadly type of brain tumor.
Hideho Okada, MD, PhD
University of California San Francisco
ACGT is funding a new clinical trial for children with a rare brain cancer.
E. Antonio Chiocca, MD, PhD
Brigham and Women’s Hospital
Using viruses to infect glioblastoma cancer cells and engage a patient’s immune system to join the fight.
Crystal Mackall, MD
Stanford University
Training CAR T cells to find and kill cancers that express the GD2 biomarker, including osteosarcoma, pediatric neuroblastoma and diffuse intrinsic pontine glioma.
Juan Fueyo, MD
MD Anderson Cancer Center
ACGT is funding research that uses an oncolytic virus to fight glioblastoma, a deadly type of brain tumor.
Hideho Okada, MD, PhD
University of California San Francisco
ACGT is funding a new clinical trial for children with a rare brain cancer.
See what's new in cell and gene therapy.
Oct 11, 2023
100% of your donation will advance research to cure all cancers.
Your donation will help develop radical new cell and gene therapies that leverage the body’s own biology and immune system to control and ultimately eradicate cancer. 100% of donations directly support scientists working on breakthrough cancer cell and gene therapy research.
Donate Today